- Home
- CVKD vs BMRA Comparison
CVKD vs BMRA Comparison
Compare CVKD & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- BMRA
- Stock Information
- Founded
- CVKD 2022
- BMRA 1971
- Country
- CVKD United States
- BMRA United States
- Employees
- CVKD N/A
- BMRA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CVKD Health Care
- BMRA Health Care
- Exchange
- CVKD Nasdaq
- BMRA Nasdaq
- Market Cap
- CVKD 29.5M
- BMRA 8.2M
- IPO Year
- CVKD 2023
- BMRA N/A
- Fundamental
- Price
- CVKD $13.34
- BMRA $2.93
- Analyst Decision
- CVKD Strong Buy
- BMRA
- Analyst Count
- CVKD 1
- BMRA 0
- Target Price
- CVKD $32.00
- BMRA N/A
- AVG Volume (30 Days)
- CVKD 24.0K
- BMRA 420.4K
- Earning Date
- CVKD 11-06-2025
- BMRA 10-14-2025
- Dividend Yield
- CVKD N/A
- BMRA N/A
- EPS Growth
- CVKD N/A
- BMRA N/A
- EPS
- CVKD N/A
- BMRA N/A
- Revenue
- CVKD N/A
- BMRA $5,311,000.00
- Revenue This Year
- CVKD N/A
- BMRA N/A
- Revenue Next Year
- CVKD N/A
- BMRA N/A
- P/E Ratio
- CVKD N/A
- BMRA N/A
- Revenue Growth
- CVKD N/A
- BMRA N/A
- 52 Week Low
- CVKD $8.74
- BMRA $2.08
- 52 Week High
- CVKD $22.90
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- CVKD 54.50
- BMRA 43.81
- Support Level
- CVKD $12.50
- BMRA $2.87
- Resistance Level
- CVKD $13.69
- BMRA $3.08
- Average True Range (ATR)
- CVKD 0.57
- BMRA 0.21
- MACD
- CVKD -0.05
- BMRA 0.01
- Stochastic Oscillator
- CVKD 73.95
- BMRA 57.97
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.